Ursela C. Jackson

Ursela C. Jackson serves as a procurement professional responsible for managing complex acquisitions in the biomedical and advanced manufacturing sectors. She plays a critical role in executing the agency’s mission to secure high-precision medical and research equipment by overseeing the full lifecycle of contract actions—from market research and solicitation to award and administration. Her portfolio primarily consists of competitive procurements under FAR Part 15, with a strong emphasis on technical evaluations and performance-based requirements. Jackson ensures compliance with federal acquisition regulations while aligning purchases with national health and scientific research priorities. Her contractor relationships are characterized by engagement with specialized manufacturers and R&D firms focused on medical instrumentation and biotechnology innovation. She routinely works with established industrial suppliers in surgical device manufacturing and emerging biotech innovators, fostering partnerships that balance scalability with technical specificity. While no single vendor dominates her portfolio, her contracting patterns reflect a preference for firms with proven expertise in FDA-regulated environments and ISO-certified production processes. Jackson’s procurement strategy is overwhelmingly non-set-aside, with 97.4% of awards issued under full and open competition, reflecting a focus on technical merit and capability over socioeconomic categorization. Nevertheless, she consistently allocates 2.6% of her acquisitions to Total Small Business Set-Asides under FAR 19.5, demonstrating a measured but intentional commitment to small business participation without compromising mission-critical requirements. Her primary procurement focus lies in NAICS 339112 (Surgical and Medical Instrument Manufacturing) and 339113 (Surgical Appliance and Supplies Manufacturing), where she procures precision instruments, sterile disposable devices, and diagnostic tools. She also frequently acquires research services under NAICS 541714 (Biotechnology R&D), indicating deep domain expertise in life sciences innovation. Her work supports advanced healthcare delivery systems and scientific advancement through technically rigorous, standards-compliant acquisitions.